ΪÑàÎÑÐÐÒµ×¢ÈëÉúÆø£¡¹ãÖÝÖÐÒ½Ò©´óѧÍŽáWGµç×Ó¹ÙÍøÊÖÒÕÍŶÓÐû²¼ÑàÎѹ¦Ð§Ö÷Òª¿ÆÑÐЧ¹û
2022-03-03
½üÄêÀ´£¬£¬£¬£¬£¬£¬£¬µ³ÖÐÑëÌá³ö“Á¢Ò졢е÷¡¢ÂÌÉ«¡¢¿ª·Å¡¢¹²Ï픵ÄÐÂÉú³¤ÀíÄ£¬£¬£¬£¬£¬£¬Íƶ¯¾¼Ã¸ßÖÊÁ¿Éú³¤£¬£¬£¬£¬£¬£¬£¬¸üºÃµØÊ©Õ¹ÔÚÐÂʱÆÚË¢ÐÂÁ¢ÒìµÄÒýÁì×÷Óᣡ£¡£¡£¡£ÔÚ´ËÅä¾°Ï£¬£¬£¬£¬£¬£¬£¬´«³ÐÓ¢»ª£¬£¬£¬£¬£¬£¬£¬ÊØÕýÁ¢Ò죬£¬£¬£¬£¬£¬£¬Íƶ¯ÖÐʽ×̲¹ÐÐÒµ¸ßÖÊÁ¿Éú³¤£¬£¬£¬£¬£¬£¬£¬³ÉΪÑàÎÑÐÐÒµÉú³¤µÄÐÂÒªÇ󡣡£¡£¡£¡£
ÖÐʽ×̲¹ÎÄ»¯ÊÇÖйú¹Å°åÎÄ»¯¹å±¦µÄÒ»²¿·Ö£¬£¬£¬£¬£¬£¬£¬Ëæ×ž¼ÃˮһÉú³¤ÓëÃñ×寷ůÔÙÆð£¬£¬£¬£¬£¬£¬£¬Ô½À´Ô½¶àÏûºÄÕßÇàíùÖÐʽ×̲¹µÄÑøÉú·½·¨¡£¡£¡£¡£¡£24Äêרע¸ßÆ·ÖÊÑàÎÑ£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍø¸ß¶ÈÖØÊÓÑз¢Á¢ÒìÊÂÇ飬£¬£¬£¬£¬£¬£¬Ò»Ö±ÖÂÁ¦ÓÚÓÃÏÖ´ú¿ÆÑпªÕ¹¶ÔÑàÎѵÄÉîÈëÑо¿£¬£¬£¬£¬£¬£¬£¬¾ò¿ÍÑàÎѵÄÓªÑø¼ÛÖµºÍ¹¦Ð§¡£¡£¡£¡£¡£Í¨¹ýÆ·ÀàÁ¢Òì¡¢¹¤ÒÕÁ¢Òì¡¢¿ÆÑÐÁ¢Òì¡¢ÌåÑéÁ¢Ò죬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÇÐʵ½â¾öÏûºÄÕßÑàÎÑ×̲¹Í´µã£¬£¬£¬£¬£¬£¬£¬ÔÚÀ©´óÆ·ÅÆÓ°ÏìÁ¦µÄͬʱ£¬£¬£¬£¬£¬£¬£¬Íƶ¯×ÅÐÐÒµÕýÏòÉú³¤¡£¡£¡£¡£¡£
ΪÉý¼¶ÑàÎÑÆ·ÖÊ£¬£¬£¬£¬£¬£¬£¬Íƶ¯ÑàÎѵĻù´¡Ñо¿£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÑз¢ÖÐÐĽ¨ÉèÑàÎÑÑо¿Ôº£¬£¬£¬£¬£¬£¬£¬ÓÉÖйú¹¤³ÌÔº¡¢ÖпÆÔºµÄר¼ÒԺʿ£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°À´×Ô½ÄÏ´óѧµÈ¶àλ×ÅÃû¸ßУ»£»£»£»£»£»ú¹¹×¨¼Ò½ÌÊÚ£¬£¬£¬£¬£¬£¬£¬×é³ÉѧÊõίԱ»á£¬£¬£¬£¬£¬£¬£¬Ö¼ÔÚÍÆ¶¯ÑàÎѵĻù´¡Ñо¿¡¢ÒÔ¼°ÓªÑø¹¦Ð§µÈ¿ÆÑ§ÁìÓòµÄ¿ÆÑÐÔ˶¯¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍø½èÖú¸ßУµÄרҵÓÅÊÆÒ»Ö±ÌáÉýÑàÎѲúÆ·Æ·ÖÊÓë¿ÆÑÐˮƽ£¬£¬£¬£¬£¬£¬£¬È¥Äê12Ô£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÐ¯ÊÖ½ÄÏ´óѧ£¬£¬£¬£¬£¬£¬£¬¿ªÆô“²ú¡¢Ñ§¡¢ÑДÉî¶ÈÏàÖú£¬£¬£¬£¬£¬£¬£¬²¢ÉèÁ¢“½ÄÏ´óѧʳÎïѧԺWGµç×Ó¹ÙÍø¿Æ´´¾ºÈü»ù½ð”£¬£¬£¬£¬£¬£¬£¬ÅäºÏÏàÖúÔö½øÑàÎÑÑз¢µÄ¸ßÖÊÁ¿Éú³¤¡£¡£¡£¡£¡£

ͼ£º“½ÄÏ´óѧʳÎïѧԺWGµç×Ó¹ÙÍø¿Æ´´¾ºÈü»ù½ð”½ÒÅÆÒÇʽ
WGµç×Ó¹ÙÍø×¢ÖØ×ÔÖ÷Á¢ÒìÄÜÁ¦µÄ½¨É裬£¬£¬£¬£¬£¬£¬²»µ«¾ß±¸ÐÂÈ˲ŵÄ×÷ÓýÄÜÁ¦£¬£¬£¬£¬£¬£¬£¬Í¬Ê±ÒԿƼ¼¸³ÄÜ£¬£¬£¬£¬£¬£¬£¬ÒÔ¿ÆÑÐӲʵÁ¦ÖúÍÆÑàÎѹ¤ÒµÍɱäÉý¼¶¡£¡£¡£¡£¡£½ñÄê2Ô£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍø¾Óɸ£½¨Ê¡¹¤ÐžֶÔWGµç×Ó¹ÙÍøÑàÎÑÑо¿ÔºÊÖÒÕʵÁ¦ÆÀ¶¨£¬£¬£¬£¬£¬£¬£¬ÀֳɻñÅú“µÚÈýÊ®¶þÅúÊ¡ÆóÒµÊÖÒÕÖÐÐÄ”³Æºô£¬£¬£¬£¬£¬£¬£¬²¢ÔÚ2ÔÂ22ÈÕ£¬£¬£¬£¬£¬£¬£¬ÀֳɾÙÐÐWGµç×Ó¹ÙÍøÑàÎÑÑо¿Ôº“¸£½¨Ê¡ÆóÒµÊÖÒÕÖÐÐÄ”½ÒÅÆÒÇʽ¡£¡£¡£¡£¡£

ͼ£ºWGµç×Ó¹ÙÍøÑàÎÑÑо¿Ôº“¸£½¨Ê¡ÆóÒµÊÖÒÕÖÐÐÄ”½ÒÅÆÒÇʽ
ÒÔÁ¢ÒìÖýÔìÓ²ºË¿ÆÑÐʵÁ¦£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÈ¡µÃÁ˷ḻµÄÑо¿Ð§¹û¡£¡£¡£¡£¡£2021Äê12Ô£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÑàÎÑÑо¿ÔººÍ½ÄÏ´óѧʳÎï¿ÆÑ§ÓëÊÖÒÕ¹ú¼ÒÖØµãʵÑéÊÒЯÊÖÍê³É²¢¿¯µÇÁËרҵÑо¿Ð§¹û¡¶Ê³ÓÃÑàÎÑÏû»¯ÎïµÄƤ·ôÃÀ°×»îÐÔÑо¿£ºÒ»ÖÖð¤ÂѰ×ÌÇÂѰס·£¬£¬£¬£¬£¬£¬£¬ÊµÑéÅú×¢£º“ÑàÎÑëÄÊÇÆäÖÐÖ÷ÒªµÄ¿¹Ñõ»¯ÒòËØ£¬£¬£¬£¬£¬£¬£¬Ð¢Ë³ÂÊΪ85.87%£¬£¬£¬£¬£¬£¬£¬ÊʺϿª·¢ÐÂÒ»´úÃÀ°×±£½¡Æ·¡£¡£¡£¡£¡£”
¿ËÈÕ£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÊÖÒÕÍŶӺ͹ãÖÝÖÐÒ½Ò©´óѧÊÖÒÕÍŶӣ¬£¬£¬£¬£¬£¬£¬·¢Ã÷ÑàÎѸ¨ÖúÖÎÁƽ᳦Ñ׵Ĺ¦Ð§£¬£¬£¬£¬£¬£¬£¬²¢Ðû²¼ÓÚ¡¶Frontiers in Pharmacology¡·£¬£¬£¬£¬£¬£¬£¬2021£¬£¬£¬£¬£¬£¬£¬4£¨12£©£¬£¬£¬£¬£¬£¬£¬Article 632602¡£¡£¡£¡£¡£Ñо¿½áÂÛÅú×¢£º“ EBN improved symptoms of colitis, reduced colonic injury, and inhibited the increases in the levels of the pro-inflammatory cytokines IL-1β and TNF-α.”£¨Ê³ÓÃÑàÎѸÄÉÆÁËÈ´³¦Ñ×Ö¢×´£¬£¬£¬£¬£¬£¬£¬¼õÇáÁËÈ´³¦ËðÉË£¬£¬£¬£¬£¬£¬£¬²¢ÒÖÖÆÁË´ÙÑ×ϸ°ûÒò×ÓIL-1βºÍTNF-αˮƽµÄÉý¸ß¡£¡£¡£¡£¡££©”¸Ã¹¦Ð§µÄ·¢Ã÷½øÒ»²½ÍØ¿íÁËÑàÎѲúÆ·µÄÓ¦Óó¡¾°£¬£¬£¬£¬£¬£¬£¬¸¶ÓëÑàÎÑÐÐÒµ¸ü¶àµÄ¿ÉÄÜÐÔ¡£¡£¡£¡£¡£

ͼ£ºWGµç×Ó¹ÙÍøÊÖÒÕÍŶӺ͹ãÖÝÖÐÒ½Ò©´óѧÊÖÒÕÍŶÓ
“·¢Ã÷ÑàÎѸ¨ÖúÖÎÁƽ᳦Ñ׵Ĺ¦Ð§”µÄÑо¿±¨¸æ
¼áÊØ¸ßÖÊÁ¿Éú³¤Ö®Â·£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÒ»Ö±ÍÆ¶¯ÖÐʽ×̲¹ÎÄ»¯ÓëÏÖ´ú¿ÆÑÐÈÚºÏÁ¢Ò죬£¬£¬£¬£¬£¬£¬ÎªÐÐÒµ»À·¢³öȫеÄÉú³¤»îÁ¦¡£¡£¡£¡£¡£Î´À´£¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍø½«¼ÌÐøÆð¾¢ÇóÐÂÇó±ä£¬£¬£¬£¬£¬£¬£¬Éî¶È¹á³¹²úѧÑÐÏàÖú£¬£¬£¬£¬£¬£¬£¬³ä·ÖÍÚ¾òÑàÎѼÛÖµ¡¢¸»ºñ²úÆ·ÀàÐÍ£¬£¬£¬£¬£¬£¬£¬ÎªÖÐʽ×̲¹ÐÐÒµµÄÁ¢Òì¿ªÍØÐÂÆ«Ïò¡£¡£¡£¡£¡£